B CELLS IN MULTIPLE SCLEROSIS

Mark P. Burgoon 1, Donald H. Gilden 1,2 and Gregory P. Owens 1

Departments of 1 Neurology and 2 Microbiology, University of Colorado Health Sciences Center, Denver, CO 80262

TABLE OF CONTENTS
1. Abstract
2. Introduction
3. Antibody in MS
4. Autoimmunity
5. B cell targets
   5.1. General considerations
   5.2. Autoimmune targets
      5.2.1. Myelin basic protein
      5.2.2. Myelin/oligodendrocyte glycoprotein
      5.2.3. Other myelin antigens
      5.2.4. Other autoantigens
   5.3. Infectious agents as antigens
      5.3.1. Herpesviruses
      5.3.2. Retroviruses
      5.3.3. Chlamydia
   5.4. Potential for infectious agent discovery
6. Importance of B cells to disease
   6.1. Characterization of the B cell response
7. Perspective
8. Acknowledgments
9. References

1. ABSTRACT

The most common laboratory abnormality in multiple sclerosis (MS) is an increased amount of cerebrospinal fluid IgG and the presence of oligoclonal bands. Despite studies of the humoral response that suggest the involvement of an infectious agent or autoantigen in disease, the major targets of the oligoclonal response are still unknown. Identification of these targets will reveal valuable insights into the cause and pathogenesis of MS and is likely to lead to effective treatment.

2. INTRODUCTION

Multiple sclerosis (MS) is the most common demyelinating disease of humans. Its prevalence in the United States is 250,000-350,000, resulting in >3,000 deaths a year, and an annual morbidity cost of more than $2.5 billion. Most MS patients develop disease between ages 15-45 years, and disease usually takes a relapsing-remitting course, although young patients infrequently develop chronic progressive MS. When disease starts after age 40 years, it is usually characterized by chronic progression that often produces serious disability within 5-10 years. Thus, late-onset MS patients may “catch up” with those who have had remitting-exacerbating disease for decades. In fact, without a history, it is difficult to distinguish an MS patient who has had remitting-exacerbating disease for 25 years from a late-onset chronic progressive MS patient who has had disease for 5 years.
mumps virus-specific antibody (5). In cryptococcal meningitis, the OGBs are adsorbed specifically with cryptococcal antigen, but not with candida antigen (6), and the OGBs in the CSF of patients with HTLV-1 myelopathy contain anti-HTLV-1 p24 antibody (7). Most recently, the oligoclonal IgG in CSF during varicella zoster virus (VZV) vasculopathy was shown to be antibody directed against VZV (8). An overview of the specificity of OGBs in CNS infectious disorders is provided in Gilden et al. (9). A further link between OGBs and infectious agents as their antigenic targets is offered by the prototypic immunopathology of chronic relapsing experimental autoimmune encephalomyelitis (EAE), produced in guinea pigs inoculated with homologous spinal cord; most of the oligoclonal IgG of these animals was removed by incubation with Mycobacterium tuberculosis contained in the Freund’s adjuvant used to help induce disease (10). Together, these findings point to the possibility that the major oligoclonal IgG in the CSF of MS patients may represent antibody to an infectious agent. This is consistent with failures to adsorb out OGBs in MS CSF with myelin or purified myelin proteins. Finally, progressive multifocal leukoencephalopathy is an exclusively human viral induced demyelinating disease (11) without any evidence of immunopathology or autoimmunity.

3. ANTIBODY IN MS

The pathologic hallmark of disease is the plaque, an area of white matter demyelination usually accompanied by inflammation. The inflammatory infiltrates are composed of T lymphocytes, some B cells and plasma cells, as well as activated macrophages or microglial cells. IgG and complement are localized primarily at the periphery of plaques (12). Although it is generally believed that inflammation is an obligatory and possibly primary feature of demyelination in MS, myelin destruction may also proceed in a context nearly devoid of lymphocytic infiltration, suggesting a role for endogenous glia (microglia or astrocytes) in mediating injury (13).

The immune response in MS suggests a possible role for antibody in the pathogenesis of disease. B cells and plasma cells are readily detected in active and late-stage MS lesions (14,15), and histological studies reveal an association of plaque Ig and complement (reviewed in Archelos et al., ref. 16). Macrophages actively engaged in myelin breakdown and contacting myelin sheaths at the plaque margin, but not elsewhere within the same MS lesion, show capping of surface IgG, implicating IgG-antigen complexes in myelin breakdown (17). Furthermore, oligodendrocytes, which undergo destruction in fresh MS plaques (18) are found within reactive astrocytes, and these cells stain positive for IgG (19). Complement proteins have also been found to co-localize with IgG in active MS lesions (20,21). In secondary progressive MS, linear groups of microglia engage short segments of disrupted myelin associated with deposits of complement, and intense staining for IgG is seen throughout the demyelinated zone. Applying multifactorial cluster analysis to very early MS lesions, Gay et al. (22) suggested that the primary lesion in MS is mediated by activated microglia and macrophages containing membrane-bound fixed complexes of both IgG and complement C3d. More recently, the activated terminal lytic complex of complement as identified by antibody to the cryptic C9 neo antigen was found exclusively co-deposited with IgG in areas of ongoing myelin breakdown (23,24). Additionally, C9 neo and IgG are found in macrophages containing myelin debris in active MS lesions, providing evidence of a direct role for complement in myelin breakdown (23). This notion is further supported by the presence of membrane attack complex-enriched membrane vesicles in MS CSF (25). Finally, a detailed histological analysis of 135 active MS lesions from 83 autopsies and biopsy specimens revealed that the most prominent pathological abnormality was demyelination associated with codeposition of IgG and activated complement (24).

4. AUTOIMMUNITY

Many investigators postulate an autoimmune basis for MS, based largely on analogy with the prototype immunopathology, EAE, as well as the detection in MS of autoreactive T cells and antibodies to various autoantigens. However, proof is wanting. EAE is a T cell-mediated demyelinating disease that can be induced in susceptible rodents and primates by immunization with homogenates of brain or myelin components and adjuvants (26,27). EAE is readily produced in syngeneic recipients by adoptive transfer of lymphocytes from animals sensitized with whole brain white matter or myelin basic protein (MBP), and antibodies to myelin components may contribute to the pathology (28,29). However, adoptive transfer of lymphocytes from MS patients to susceptible mice has rarely induced demyelination (30,31), and there is only a single report of demyelination produced by passive transfer of antibody from MS patients (32). Although MS is considered by some investigators as a strictly CD4+ T cell-mediated disease, histopathologic studies of active lesions indicate a more complex pattern of disease and implicate additional or alternative modes of demyelination in the pathogenesis of MS (24). Also, it has never been shown that abundant brain white matter proteins, such as MBP or myelin oligodendrocyte glycoprotein (MOG), bind to or adsorb out the OGBs in MS. Careful examination of plaques from patients with progressive MS has not revealed IgG binding to the surface of intact myelin sheets, even in the presence of IgG-positive plasma cells (33); thus if anti-myelin antibody contributes to myelin breakdown in chronic MS lesions, the determinant does not appear to be an antigen on the surface of intact healthy myelin sheaths. The collective abundant data gathered on immunogenetic background, macrophage function, specific T-cell subpopulations and cytokine and chemokine responses in EAE and in MS patients has failed to clarify the nature of disease production.

Equally discouraging is that the multiple immunosuppressive and immunomodulating agents used to treat MS have not produced the gratifying response often seen in myasthenia gravis, a proven autoimmune disease. MS is also believed to be immunopathologic or
B cells in multiple sclerosis

autoimmune based on the ability of various interferons to modify disease in study periods of 3 years or less (34,35). Putative mechanisms (reviewed in Noseworthy et al., ref. 36) include the reduction of T cell proliferation and the production of tumor necrosis factor-alpha, altered cytokine production, increased secretion of interleukin-10, and reduction of the passage of immune cells across the blood brain barrier by affecting adhesion molecules, chemokines and proteases. However, interferons are proteins produced by cells shortly after virus infection, so that the benefit, if any, of synthetic interferons in MS might rest in their ability to suppress chronic or intermittent virus infection (37). For example, acyclovir, an effective antiviral drug used to treat infection produced by multiple herpesviruses, reduced the incidence of exacerbations by 34% compared to placebo when MS patients took 800 mg of acyclovir three times daily for 2 years (38). Although seemingly heretical, it was recently suggested that a moratorium be placed on the autoimmune hypothesis in MS to redirect funds for research on novel approaches to the problem (39).

5. B CELL TARGETS

5.1. General considerations

Although antibodies to multiple infectious and autoantigens have been found in MS patients, the specificity of the oligoclonal IgG in MS brain and CSF remains unknown. Logical questions arise about whether antibody is (a) specific for disease, i.e., part of the host immune response to the agent that causes MS; (b) a major component of the immune response, particularly in the CNS; and (c) part of a non-beneficial host immune response and related to pathogenesis. Controls for antibodies that are secondary to the disease process have been lacking in many studies of MS, and must be considered in future studies. The detection of specific antibodies in MS patients, but not in control patients with CNS disease assumes significance only when the control patients have inflammatory CNS disease. Furthermore, a characteristic feature of MS is the presence of OGBs in CSF that are absent in blood (40,41). Resolution of brain and CSF proteins by isoelectric focusing reveals both polyclonal IgG, as seen in the CNS of healthy patients, as well as oligoclonal IgG, visualized as discrete bands in the cathodal region of the gels. The absence of several of these OGBs in matched serum samples is evidence of intrathecal synthesis. Finally, the contribution of antibody reactivity to the total host immune response must be analyzed. Since the major oligoclonal response in infectious diseases of the nervous system is directed against the agent that causes disease, every attempt must be made to determine the specificity of the oligoclonal IgG in MS. Antibodies to various infectious agents and autoantigens that are not part of the oligoclonal IgG repertoire are likely to be irrelevant, although the demonstration of a direct link between such minor antibody responses and the disease process would be significant. Meanwhile the detection of any antibody in MS that is synthesized intrathecallly is worthy of further study.

5.2. Autoimmune targets

Many studies have identified autoantibodies directed against CNS antigens in MS patients (16,42,43). However, these anti-brain antibodies are not restricted to MS. For example, Traugott et al. (44) detected anti-brain antibodies, as evidenced by their ability to stain oligodendrocytes or astrocytes from bovine or human brain sections, in 63% of MS sera, in 43% of patients with other neurological diseases (both inflammatory and noninflammatory) and in 29% of normal patients. In the same study, sera from about 50% of stroke patients stained oligodendrocytes (44). Initially, anti-myelin antibodies were found in serum of 88% of normal adults, with a “somewhat higher titer in sera from patients with amyotrophic lateral sclerosis (88%) and MS (100%)” (45). Steck and Link (46) detected anti-oligodendrocyte antibodies and antibody levels in CSF and serum of 12 MS patients that did not differ significantly from 25 control patients, including 10 with aseptic meningitis and 7 with cerebrovascular disease. The presence of anti-myelin antibodies in patients with stroke probably reflects antibody to brain antigens released from an immunologically privileged site. Other studies have reported autoantibodies to specific brain antigens (summarized below), although these antibodies are also not MS-specific.

5.2.1. Myelin basic protein

The most extensively studied candidate autoantigen in MS is myelin basic protein (MBP), found at the cytoplasm-membrane interface of oligodendrocytes and comprising 30% of CNS myelin (47,48). Increased antibody titers to MBP or MBP peptides were detected by radioimmunoassay in 17-96% of MS CSF and were related to disease activity (49,50). But apart from increased activity in 88% of patients with optic neuritis, no control CSFs were examined in these studies. Further, an immunospot assay detected antibodies to MBP in CSF of 89% of MS patients, compared to 67% of optic neuritis patients and 22% of patients with other neurological diseases including two patients with inflammatory conditions (Lyme neuroborreliosis and retinochorioidosis) (51). Olsson et al. (52) also found similar proportions of anti-MBP or anti-myelin IgG-producing cells in CSF from 27 of 34 (79%) MS patients, but also found both in CSF from 4 of 14 (29%) control patients with acute aseptic meningoencephalitis. The greater number of antibodies to MBP and anti-myelin IgG-producing cells in MS most likely reflects the chronic nature of MS, with more antibody production over time compared to a monophasic infectious disorder. More recently, immunoblotting and ELISA demonstrated anti-MBP reactivity in sera of 28% of MS patients, compared to 47% of patients with other infectious neurologic diseases, 23% of other non-infectious neurologic diseases, and 60% of rheumatoid arthritis patients; noting the enhanced anti-MBP responses in the infectious and inflammatory disease control subjects, the authors suggested that MBP reactivity was not specific for MS (53).

Cruz et al. (54) linked the anti-MBP reactivity in MS CSF to minor bands that were part of the polyclonal response in about one-third of MS patients. More recently, O’Connor et al. (55) attempted to characterize the affinity of anti-MBP antibodies in serum and CSF of MS patients using a solution-phase radioimmunoassay, which is less likely to detect low-affinity antibody/antigen interactions.
that might be due to excess antigen fixed to a plate or multimeric presentation in a solid-phase ELISA; they only detected autoantibodies to MBP by ELISA, suggesting that moderate- or high-affinity antibodies against MBP were not expressed in MS patients. The detection of low-affinity or low-level anti-MBP antibodies in MS is consistent with other studies that failed to detect anti-MBP antibodies in the CSF by various methods (56,57). The disparities in measuring anti-MBP activity in MS patients, combined with the widespread detection of activity in control groups, indicate that anti-MBP antibodies are not specific for MS.

5.2.2. Myelin/oligodendrocyte glycoprotein (MOG)

MOG is a strongly immunogenic but minor component of myelin that is expressed exclusively on the outermost lamella of the myelin sheath (48). MOG is a dominant target for the demyelinating autoantibody in EAE induced by immunization with CNS homogenates (58,59). Antibodies to MOG have been identified by ELISA and immunoblotting in CSF of only 7 of 30 (23%) MS patients compared to 2 of 30 (7%) patients with other neurologic diseases (60). The additional detection of antibody to MOG in CSF of one patient with encephalitis and one with cerebrovascular disease raises the possibility that anti-MOG activity is secondary to tissue destruction. Genain et al. (61) identified myelin degeneration in three MS brains by colocalization of gold-labeled MOG peptides, presumably by their binding to anti-MOG antibody. No MOG-labeled plasma cells were found in brain, although others have reported sequestration of MOG-specific B-cells in brain (62). However, other studies did not find a significantly higher prevalence or level of anti-MOG antibody in CSF of MS patients compared to patients with other neurologic diseases (53,63). A recent attempt to attribute the demyelinating activity in MS patients to anti-MOG antibodies, by linking particular MOG epitopes to MS that are associated with demyelination in EAE, revealed such specificities in the serum from only 1 of 17 MS patients (64). Most recently, another study linked anti-MOG antibodies to more rapid development of clinically definite MS in patients after a first demyelinating event (65). Overall, anti-MOG antibodies may simply represent a secondary rather than a causative effect in instances of more severe demyelination.

5.2.3. Other myelin antigens

Other myelin antigens have been studied in MS. The 2', 3' –cyclic nucleotide 3' phosphodiesterase (CNP1), present on the surface of oligodendrocytes, has been described as a major autoantigen for CSF IgM in MS patients and reacted with serum antibody in 52 of 70 (74%) MS patients compared to 3 of 33 (9%) patients with other neurologic diseases (66). However, the specificity of the immune response to CNP1 was assessed with highly enriched fractions of CNP. In addition, the anti-CNP1 activity, defined as the amount of CNP1 that co-purified with CSF antibody, was compared only to MBP that copurified with CSF Ig and not to the entire mixture of purified antigens, questioning whether CNP1 is the most prevalent antigen. Further, no IgG response to CNP1 was found, although IgG comprises the major oligoclonal response in MS CSF (67,68). Warren et al. (50), using solid-phase radioimmunoassay (RIA) to examine the antibody response in CSF to the most abundant myelin component, proteolipid protein (PLP), detected anti-PLP reactivity in CSF from 9 of 385 patients with MS (2%), compared to 6 of 55 (11%) patients with optic neuritis, and no other control patients were tested. An additional study found only 5 of 370 (1%) MS patients with elevated anti-PLP in their CSF (49). For myelin-associated glycoprotein (MAG), solid-phase RIA revealed a statistically significant two-fold increase in anti-MAG activity in CSF from 10 MS patients compared to 12 SSPE patients, 14 patients with other neurological diseases and 10 normal controls. However this reactivity was detected only in CSF and only with the most sensitive technique (RIA) applied (69), suggesting a low level of immunity to MAG. Andersson et al. (70) also identified increased humoral reactivity to MAG in MS patients, as well as in patients with polyneuropathy, but disease could not be correlated with particular MAG peptide epitopes. In 7 patients with relapsing-remitting MS, immunoblotting identified antibodies in CSF that recognized a band corresponding to the oligodendrocyte-specific protein (OSP), as well as additional uncharacterized bands; this reactivity was not seen in two non-inflammatory control CSFs (71). In additional screens using ELISA, 80% of relapsing-remitting MS patients had anti-OSP values that were above an arbitrary setting of 0.55, with all 20 control CSFs below the value. However, the authors were not able to correlate anti-OSP reactivities to secondary progressive MS patients.

5.2.4. Other autoantigens

Autoantigens in addition to myelin-specific antigens have been reported in MS, several of which are not CNS-specific. These antigens include aß-crystallin (72), heat-shock proteins (73), transaldolase (74,75), proteasomes (76), and DNA (77). Other studies found no increased responses in MS patients or disease specificity for several of these autoantigens (78,79). Overall, a convincing link between any autoimmune antigen and the pathogenesis or major humoral response in MS has not been established.

5.3. Infectious agents as antigens

Various microorganisms have been associated with MS, but none has been tightly linked to disease (80). Although intrathecal synthesis of antibodies against viruses has been a common finding (81,82), including early reports of reactivities to measles virus, rubella, mumps, parainfluenza 1, herpes simplex, varicella, and vaccinia (83-85), these reactivities were attributed to only some patients or a minor fraction of the intrathecally synthesized IgG in MS, and did not correlate with disease duration or severity (4,86,87).

5.3.1. Herpesviruses

In the past decade, two human herpesviruses have also been associated with MS. One is human herpesvirus-6 (HHV-6), the cause of roseola, and the other is Epstein-Barr virus (EBV), which causes infectious mononucleosis (88-92). The detection of fingerprints of these two ubiquitous viruses known to be latent in blood B- (EBV) or T- (HHV-6) cells is intriguing, since the primary encounter
B cells in multiple sclerosis

with either virus usually occurs before or during puberty, the same time that epidemiologic evidence indicates exposure to the disease-causing agent of MS. However, HHV-6 is found not only in brain and CSF of MS patients, but also in neoplastic and normal brain (93), suggesting that the detection of virus reflects its reactivation from latency and/or blood T cells trafficking through brain. Other reports do not support an association between HHV-6 and MS. One study found serum IgM responses to HHV-6 in only 1 of 55 MS patients, and IgG responses in 15 of the patients (94). Using PCR, other groups have not detected HHV-6 in MS, and have not shown HHV-6 antibody titers different from those in controls (95,96). Furthermore, no EBV-specific RNA was detected in 10 MS brains by in situ hybridization (97).

5.3.2. Retroviruses

Several groups have studied the human endogenous retrovirus HERV-H in MS (98), which is an element of the human genome. Activation of HERV-H was detected when specific cell types (mainly B cells) of MS patients were cultivated in vitro (99), and the virus was isolated from a clonal line of leptomeningeal cells from an MS patient (100). Elevated levels of antibodies against HERV-H peptides have been found in the serum and CSF of MS patients (101), although a detailed study of MS patients in Sardinia identified HERV-H not only in the CSF of 50% of MS patients, but also in 40% of control patients (102). HERV-H is also occasionally present in synovial fluid of rheumatoid arthritis patients (103). Overall, HERV-H is not strongly linked to MS and its detection may reflect the inflammatory response.

5.3.3. Chlamydia

The most recent organism to be implicated is Chlamydia pneumoniae, a gram-negative bacterium. Since the original detection of Chlamydia pneumoniae DNA and antibody in CSF of some MS patients (104), various laboratories around the world attempted to confirm this potentially important finding. However, multiple studies have indicated a lack of any significant association between Chlamydia pneumoniae and MS (reviewed in Tsai and Gilden, ref. 105).

5.4. Potential for infectious agent discovery

Although early attempts have failed to identify the putative “MS virus” by cocultivation and fusion of MS brain cells with indicator cells, or by inoculation of MS brain into experimental animals (reviewed in Gilden et al., ref. 9), the search for virus needs to be continued. The potential to identify rare or low-abundance pathogens has improved, and the molecular virologic strategies and techniques available today allow studies of virus detection not possible 20 years ago. For example, the ability to prepare and characterize libraries of genes from human tissue based on a difference in their genes or gene products allowed the isolation of cDNA clones derived from hepatitis-C virus (HCV), without prior knowledge of the virus, the viral genome, or presence of circulating viral antibodies (106). Of particular interest is that the abundance of HCV-specific RNA from infected animals was ultimately determined to be only ~0.00001% or 1:10^9.

Combined cloning in expression vectors (even without subtraction hybridization) and immunologic screening led to the identification of an HCV-specific clone in ~10^9 recombinant phage (106). These sensitive techniques may detect a novel or low-abundance pathogen in MS patients that triggers disease and becomes the major target for the oligoclonal response.

6. IMPORTANCE OF B CELLS TO DISEASE

Although the role of B cells in the pathogenesis of MS is still unknown, it is possible that B cells and plasma cells produce antibody against an as yet unidentified infectious agent (antigen) that causes MS. These cells might also produce autoantibodies against specific myelin antigens to damage myelin membranes, or autoantibodies that participate in anti-idiotypic networks that might regulate the course of MS (43). The presence of IgG in the CNS of MS patients has been well established, but IgG binding to the surface of intact myelin sheaths, even in the immediate presence of IgG-positive plasma cells, has not been confirmed. These findings, together with the fact that complement coupling dramatically increases the immunogenicity of potential antigens (107), point to the presence of a cryptic antigen located within disrupted myelin close to plaques as the source of the putative MS antigen (33).

6.1. Characterization of the B cell response

Mattson et al. (108,109) showed by isoelectric fousing that the OGB profiles in different plaques of the same MS brain overlap but are not identical at each plaque, in contrast with SSPE patients in whom OGBs from different brain regions revealed almost identical patterns. Some investigators have attributed this pattern of IgG expression in MS brain and the apparent absence of OGB specificity to non-specific or bystander-activation of B cells randomly recruited into the CNS (110). However, the somatic mutation and repertoire shifts that occur in antibodies after repeated exposure to antigen might also produce the different OGB profiles.

To further address the significance of the humoral response in MS, several laboratories, including ours, have used PCR methodologies to amplify and analyze the variable region sequences of immunoglobulins (Igs) produced by plasma cells and B cells in MS lesions and CSF. Analysis of heavy chain variable region (VH) sequences expressed in plaque regions of several MS brains revealed a restricted Ig repertoire indicative of a targeted humoral response (111-114). Oligoclonal VH populations were readily detected in each of the MS repertoires and displayed features indicative of affinity maturation, including extensive somatic mutation and the preferential accumulation of replacement mutations in complementarity-determining regions. In one MS brain, ~33% of the IgG transcripts comprised a single clonal population, and many of the dominant VH sequences from this brain were found in multiple plaque sites (111). Intraclonal diversification indicative of clonally expanded B cell populations and the preferential utilization of specific family germline segments were also observed in
B cells in multiple sclerosis

many of the MS repertoires. A comparison of VH sequences from MS plaques and those in SSPE brain revealed no significant differences in the degree or character of somatic mutations (113). The humoral response in SSPE brain is an antigen-driven response directed against measles virus, the cause of disease, and several of the prominent IgG populations in the SSPE brains studied have been demonstrated to react with specific measles virus proteins (115,116).

Clonally expanded B cell populations have also been detected in the CSF of MS patients and inflammatory neurologic controls (including acute disseminated encephalomyelitis and viral encephalitis), but not in all non-inflammatory neurologic control CSFs (including migraine, amyotrophic lateral sclerosis, and spinocerebellar degeneration, postinfectious myelitis, and epilepsy) (117-120). As in plaque regions, the CSF VH repertoire is restricted, and sequence analysis reveals extensive somatic mutation and intraclonal diversification. Furthermore, the accumulation of intrathecal B cell clones occurs early in disease. Features of the VH repertoire found in MS plaques and CSF are also detected in the CSF of some individuals sampled during their first clinical attack (clinically isolated syndrome). A subsequent follow-up of these subjects shows a high conversion rate to definite MS for those patients with prominent B cell clonal expansion (118).

The antibodies expressed in MS plaques and CSF appear to be preferentially targeted to the CNS. Colombo et al. (119) found that two of the three most overrepresented VH sequences in MS CSF were not amplified from blood lymphocytes using clone-specific PCR primers, and a comparison of the IgG repertoire of an MS plaque to that in peripheral blood lymphocytes of the same MS patient revealed no overlap between the two VH repertoires (114).

The combined use of fluorescence-activated cell sorting or microdissection techniques with PCR has enabled the single-cell analysis of the rearranged heavy and light chain variable regions of antibodies in B and plasma cells (121,122). Using this approach, our group sorted the CD19+ B cell population in the CSF of several MS patients and amplified the V region sequences of single B cells by RT-PCR. Confirming the conclusions drawn from previous analyses, clonally expanded B cell populations were readily detected in all of the MS patients (120). The most important implication of identifying rearranged heavy and light chain V-region sequences at the single-cell level is the ability to accurately recreate recombinant Abs from those populations, which can then be used to search for disease-relevant antigens in MS.

7. PERSPECTIVE

A major challenge will be to identify relevant Ig produced by B or plasma cells. The antibody in MS plaques might be directed against the causative infectious agent or against a relevant autoantigen, whereas some Ig will be directed against an irrelevant antigen(s) released from the brain during destruction. Both relevant and irrelevant antibodies may be likely since memory B cells that are able to switch their antibody specificity away from the immunizing antigen can be maintained over long periods of time (123). Despite the great number of studies of the B cell response in MS, the targets of the oligoclonal response have yet to be determined. This oligoclonal response, one of the diagnostic hallmarks of MS, is likely to provide valuable insights into the cause or pathogenesis of this debilitating disease.

8. ACKNOWLEDGMENTS

Supported in part by Public Health Service Grants NS 32623 and NS 41549 from the National Institutes of Health. We thank Marina Hoffman for editorial review and Cathy Allen for preparing the manuscript.

9. REFERENCES

B cells in multiple sclerosis


34. Paty D. W., D. K. Li, UBC MS/MRI Study Group & IFNB Multiple Sclerosis Study Group: Interferon beta-1b is
B cells in multiple sclerosis


59. Lintoning C. & H. Lassmann: Antibody responses in chronic relapsing experimental allergic encephalomyelitis:
B cells in multiple sclerosis

correlation of demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 17, 61-69 (1987)


B cells in multiple sclerosis


B cells in multiple sclerosis


**Key Words:** Multiple Sclerosis, MS, B cells; antibodies, Oligoclonal Bands, Review, CNS, Central Nervous System, Neurologic Disease, Review

**Send correspondence to:** Mark P. Burgoon, Ph.D., Department of Neurology, University of Colorado Health Sciences Center, 4200 E. 9th Avenue, Mail Stop B182, Denver, CO 80262, Tel: 303-315-3727, Fax: 303-315-8720, E-mail: mark.burgoon@uchsc.edu